Prospective interventional study assessing the effectiveness on ameliorating surgical stress and the enhancement of recovery after surgery by Miyagi Cancer Center Head and Neck ERAS Protocol (MCC-HN ERAS) - ERAS protocol for head and neck cancer at Miyagi Cancer Center (MCC-HN-ERAS)

Miyagi Cancer Center0 sites60 target enrollmentDecember 19, 2017

ConditionsHead and Neck Cancers

Overview

Phase: 未知
Intervention: Not specified
Conditions: Head and Neck Cancers
Sponsor: Miyagi Cancer Center
Enrollment: 60
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The duration of hospital stay: Median 25 days. The duration until completion of the discharge criteria: Median 17 days. Early mobilization: 86.0% (POD1), 96.5% (POD2). Enteral nutrition: 80.1% (POD1), 100% (POD2). Postoperative pain: Mean VAS scores of 1.51 to 3.13. Clavien Dindo grade II or higher postoperative complications: 27.6% of the patients. The mean QOR40 score: 179.6 preoperatively, 146.1 at POD3, and 167.8 at POD7.

Registry

who.int

Start Date

December 19, 2017

End Date

March 31, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Miyagi Cancer Center

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\) Patients with hypersensitivity to dexamethasone. 2\) Patients with active infectious diseases such as tuberculosis, viral infection and mycosis. 3\) Patients with thrombosis. 4\) Patients with poor\-controlled diabetes mellitus; e.g. insulin dependent. 5\) Patients with uncontrolled psycogenic disease, such as depression. 6\) Patients with active peptic ulcer. 7\) Patients with uncontrolled glaucoma. 8\) Patients with regular use of oral steroid for such conditions as autoimmune disease.